comparemela.com
Home
Live Updates
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma : comparemela.com
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma
European Orphan Drug Designation qualifies NXC-201 for: 10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for: EU protocol...
Related Keywords
Gabriel Morris
,
Mike Moyer
,
Ilya Rachman
,
European Commission
,
Exchange Commission
,
Company Annual Report On Form
,
European Medicines Agency
,
European Union
,
Nasdaq
,
Committee For Orphan Medicinal Products
,
Immix Biopharma Inc
,
Company Contact
,
European Orphan Drug Designation
,
Chief Executive Officer
,
Chief Financial Officer
,
Immix Biopharma
,
Single Day
,
Cellular Therapy
,
Orphan Medicinal
,
Orphan Drug Designation
,
Annual Report
,
comparemela.com © 2020. All Rights Reserved.